Article Text

Download PDFPDF
Adalimumab trough concentrations in patients with rheumatoid arthritis and psoriatic arthritis treated with concomitant disease-modifying antirheumatic drugs
  1. E H Vogelzang1,
  2. M F Pouw1,2,
  3. M Nurmohamed1,
  4. E L Kneepkens1,
  5. T Rispens2,
  6. G J Wolbink1,2,
  7. C L M Krieckaert1
  1. 1 Department of Rheumatology, Jan van Breemen Research Institute | Reade, Amsterdam, The Netherlands
  2. 2 Department of Immunopathology, Sanquin Research and Landsteiner Laboratory Academic Medical Centre, Amsterdam, The Netherlands
  1. Correspondence to Erik Hans Vogelzang, Jan van Breemen Research Institute|Reade, Dr Jan van Breemenstraat 2, Amsterdam 1056 AB, The Netherlands; e.vogelzang{at}

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Several factors—including immunogenicity—influence pharmacokinetics of adalimumab. The formation of antidrug antibodies (ADAb) leads to lower adalimumab trough concentrations in patients with rheumatoid arthritis (RA) or psoriatic arthritis (PsA),1 ,2 and thus associated with a diminished clinical response.3 A previous paper demonstrated that methotrexate (MTX) had a dose-dependent effect on the percentage of patients that tested positive for ADAb against adalimumab.4 Moreover, prior research has shown that patients with RA concomitantly treated with MTX had higher adalimumab trough concentrations than patients without, which was also dose dependent, resulting in a more frequently achieved European League Against Rheumatism good response status.5 ,6 These studies suggest an additional beneficial effect of concomitant MTX therapy for patients with RA treated with adalimumab. However, in PsA, the benefit of MTX is not yet clear.7 Also, some patients do …

View Full Text


  • Contributors All authors were responsible for study concept and design, clinical revision and drafting of the manuscript for important intellectual content, and approved the final version of the manuscript to be published. EHV and CLMK were responsible for acquisition of data. EHV, MFP, GW and CLMK were responsible for analysis and interpretation of data. MN and GW obtained funding. GW and CLMK supervised the study.

  • Competing interests MN reports having received consultancy fees from Abbott, Roche, Pfizer, MSD, UCB, SOBI and BMS, payment for lectures from Abbott, Roche and Pfizer. TR reports having received payments for lectures from Pfizer and Abbvie. GJW reports having received a research grant from Pfizer (paid to the institution) and payments for lectures from Pfizer and Amgen. CLMK reports having received payment for lectures from Pfizer and Abbvie.

  • Patient consent Obtained.

  • Ethics approval Medical ethics committee of the Slotervaart Hospital and the Jan van Breemen Research Institute|Reade.

  • Provenance and peer review Not commissioned; externally peer reviewed.